HEALTHCARE INVESTMENTS
PHARMACEUTICALS & BIOTECHNOLOGY
ARKIN BIO
Arkin Bio identifies, invests in, and accompanies innovative early and mid-stage companies with game-changing breakthroughs in areas such as: immunotherapy, cancer, metabolism, microbiome, CNS, autoimmune diseases, orphan diseases and drug delivery platforms.
The experienced Arkin Bio ’ management team, leads and supports its portfolio companies through the hurdles of drug development, towards the proof of concept stage and beyond, to significant value creation.
Arkin Bio is currently invested in companies in various stages of product development.
DR. PINI ORBACH – HEAD OF PHARMA
Dr. Pini Orbach joined Arkin Holdings in 2010 as head of its pharma division. He sits on the board of several of Arkin’s pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, with which he shares his extensive hands-on experience in drug development and business.
Dr. Orbach’s gained his professional record in US-based companies such as Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ: EPIX), as well as Israel-based companies such as cCAM BioTherapeutics, a cancer immunotherapy company sold to Merck in 2015 for $605M.
He holds a Ph.D from the department of physiology and functional genomics at the University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School, Massachusetts General Hospital.
